Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.978195
Keywords
colorectal cancer; CAR T cells; immunotherapies; tumor microenvironement; tumor mutational burden; clinical data
Categories
Funding
- Moroccan Ministry of Higher Education, Research and innovation
- Moroccan Ministry of Higher Education, Research and innovation
- Digital Development Agency ADD
Ask authors/readers for more resources
CAR T-cell therapy is a promising genetically engineered cell-based immunotherapy for cancer, but its application in solid tumors, including colorectal cancer, is still in the early stages. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment.
Chimeric antigen receptor (CAR) T-cells represent a new genetically engineered cell-based immunotherapy tool against cancer. The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies. Unfortunately, there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer. CAR T-cell therapy for colorectal cancer is still in its early stages, and clinical data are scarce. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment for CAR T-cell therapy in colorectal cancer. In this review, we summarize current knowledge, highlight challenges, and discuss perspectives regarding CAR T-cell therapy in colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available